Therapeutic approaches to cerebral vasospasm complicating ruptured aneurysm

Mohamed Barbarawi,1 Sarah F. Smith,2 Mohamed Abu Jamous,1 Hazem Haboub,3 Qudsieh Suhair,4 Shboul Abdullah1
1Department of Neurosurgery, 2Department of Radiology; King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan; 3Department of Neurosurgery Royal North Shore Hospital St. Leonards, Australia; 4Hashemite University, Faculty of Medicine, Zarqa, Jordan

Abstract

Cerebral vasospasm is a serious complication of ruptured aneurysm. In order to avoid short- and long-term effects of cerebral vasospasm, and as there is no single or optimal treatment modality employed, we have instituted a protocol for the prevention and treatment of vasospasm in patients suffering aneurysmal sub-arachnoid hemorrhage (SAH). We then reviewed the effectiveness of this protocol in reducing the mortality and morbidity rate in our institution. In this study we present a retrospective analysis of 52 cases. Between March 2004 and December 2008 52 patients were admitted to our service with aneurysmal SAH. All patients commenced nimodipine, magnesium sulphate (MgSO4) and triple H therapy. Patients with significant reduction in conscious level were intubated, ventilated and sedated. Intracranial pressure (ICP) monitoring was used for intubated patients. Sodium thiopental coma was induced for patients with refractory high ICP, angiography was performed for diagnosis and treatment. Balloon angioplasty was performed if considered necessary. Using this protocol, only 13 patients (25%) developed clinical vasospasm. Ten of them were given barbiturates to induce coma. Three patients underwent transluminal balloon angioplasty. Four out of 52 patients (7.7%) died from severe vasospasm, 3 patients (5.8%) became severely disabled, and 39 patients (75%) were discharged in a condition considered as either normal or near to their pre-hemorrhage status. Our results confirm that the aforementioned protocol for treatment of cerebral vasospasm is effective and can be used safely.

Introduction

Cerebral vasospasm (CV) is the most significant cause of high mortality and morbidity in patients suffering aneurysmal sub-arachnoid hemorrhage (SAH); but it may also occur after head injury.1 The precise pathogenesis of vasospasm is still poorly understood but seems to be related to the products of the erythrocyte breakdown.2 This entity is a multifactorial problem and is highly correlated with poor clinical grade at presentation and the amount of blood in the subarachnoid space. The site of the aneurysm, the presence of hypotension, hyponatremia, hypovolemia, hyperthermia, high intracranial pressure, intraventricular hemorrhage, the use of antifibrinolytic agents, smoking, and the age of the patient are also considered as risk factors for CV.3-5

Typically, CV occurs on about the fourth day after SAH and usually peaks between seven and ten days. Diffuse or worsening headache with irritability are usually the initial symptoms; altered level of consciousness and the appearance of a new focal neurological deficit are other hallmarks of clinical vasospasm.3 Multimodal treatments for CV have been adopted by various institutions, but no consensus has yet been reached on the optimal protocol.4 Here we introduce the protocol used in our practice to deal with patients suffering from ruptured aneurysm and at risk of developing clinical vasospasm, and then discuss the results obtained from applying this protocol over the last four years. In comparison with other protocols used we concluded that our protocol is safe and effective.5,5

Materials and Methods

The study was approved by the ethical committee for human research (IRB) at Jordan University of Science and Technology. Our study population consisted of 52 patients treated only for aneurysmal SAH in King Abdullah University Hospital between March 2004 and April 2008 (Table 1). The diagnosis was based on the clinical presentation of ruptured aneurysm, a CT scan positive for SAH, and the presence of aneurysm on digital subtraction angiography (DSA). Lumbar puncture to check for erythrocytes or xanthochromia in the CSF was performed for diagnosis and treatment modality employed, we have insti-...
against CV. All patients were admitted to the intensive care unit. Intravenous fluids were commenced at a rate of 1.7 mL/kg/h of normal saline 0.9% versus glucose water 5%. Systolic blood pressure was maintained between 120 and 160 mmHg and raised up to 180 as indicated in patients with secured aneurysm. Oxygen saturation was maintained at >95% for at least 14 days and longer if vasospasm developed. Nimodipine was given for 21 days as an intravenous infusion of 20 mcg/kg/h from the day of admission for up to two weeks, and then continued at 60 mcg/4h orally for another week if there was no evidence of vasospasm. In the presence of vasospasm, nimodipine was continued intravenously for 21 days. MgSO4 20 mEq/L in 0.9% Normal saline was also given to maintain the serum magnesium double the normal level between 1.5 and 2 mmol/L for 10-14 days (average 40-80 mEq/d).

When patients developed symptoms suggestive of clinical vasospasm, a non-contrast CT scan was repeated to rule out re-bleeding, hydrocephalus cerebral edema, or ischemic changes. Patients with a significant decline in level of consciousness (GCS fall of more than two points) were intubated, ventilated and sedated using morphine and midazolam at a rate of 5 mg/h each. Intracranial pressure (ICP) was monitored on all intubated patients. For all patients with new symptoms suggestive of vasospasm, with a negative CT scan and no metabolic disorders, to explain the symptoms, cerebral angiography was repeated to confirm the diagnosis and to reverse the narrowed segments with selective injection of vasodilators (papaverine vs. nimodipine) into the cerebral arteries in spasm. Intraarterial vasodilators was repeated for patients with persistent vasospasm. Transluminal balloon angioplasty was also used when necessary in patients with symptomatic proximal vasospastic segments who did not respond to the medical treatment.

Although not a specific treatment option for CV, administration of barbiturates has been applied in the management of patients in our department who continued to display refractory cerebral vasospasm with a significant decline in conscious level (GCS below 9/15) and intractable high ICP to provide adequate cerebral protection during vasospasm. When required, intravenous sodium thiopental (STP) was used at a rate of 3-4 mg/kg/h after a bolus dose of 10 mg/kg over one hour, with therapeutic endpoint being control of ICP or its side effects such as sepsis or hypotension.

### Results

Using this protocol, 13 (25%) of the 52 patients admitted with aneurysmal subarachnoid hemorrhage had symptomatic vasospasm requiring aggressive treatment (8 males, 5 females; male:female ratio 1.6:1). Three patients were Fisher grade 2, 7 patients grade 3, and the rest grade 4. The anterior communicating artery was the site of ruptured aneurysm in 8 patients with clinical vasospasm (Figure 1), while the posterior communicating, terminal carotid and middle cerebral arteries were the origin in 5 cases. Six patients required intraarterial vasodilators for prolonged vasospasm. Transluminal balloon angioplasty was successfully performed in 3 patients (Figure 2A and B). Ten patients received barbiturates; administration was stopped early in 2, the first a young woman who developed fixed dilated pupils on the following day and the other a patient who sustained a high fever with leukocytosis after two days. He continued to decline until he died from vasospasm three days later. STP was used for 1-5 (average 3.5) days.

### Patient outcomes

Four, all of whom had anterior communicating artery aneurysm, of the 52 patients (7.7%) died of severe vasospasm. Another 6 patients (11.5%) died of other causes, 3 from re-bleeding, 2 from pulmonary embolism and one from sepsis, giving an overall mortality rate of 19.2%. Three patients (5.8%) survived with significant disability requiring ongoing nursing care (Figure 3A and B). The remaining patients (75%) were discharged in either normal condition or with minor neurological deficit. Two patients experienced mild hemiparesis and sensory changes which recovered well over time (Table 3). However, some patients experienced variable clinical signs identical to those of symptomatic vasospasm. One developed a progressive decline in conscious level; CT scan revealed active communicating hydrocephalus but he made a good recovery after placement of a ventriculo-peritoneal shunt. Another patient became depressed with behavioral changes. Investigative tests resulted normal and she respond-

**Table 1. Demographic details.**

<table>
<thead>
<tr>
<th>Sex</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28 (53.8%)</td>
<td>24 (46.2%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45</td>
<td>20-72</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sex</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28 (53.8%)</td>
<td>24 (46.2%)</td>
</tr>
</tbody>
</table>

**Table 2. Distribution of patients with aneurysmal SAH by artery of origin.**

<table>
<thead>
<tr>
<th>Artery of origin</th>
<th>Number of patients (% of total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior communicatig</td>
<td>22 (42.3)</td>
</tr>
<tr>
<td>Posterior communicatig</td>
<td>15 (28.8)</td>
</tr>
<tr>
<td>Middle cerebral</td>
<td>5 (9.6)</td>
</tr>
<tr>
<td>Terminal internal carotid</td>
<td>4 (7.7)</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>2 (3.9)</td>
</tr>
<tr>
<td>Supraclinoid internal carotid</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Multiple locations</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Basilar tip</td>
<td>2 (3.9)</td>
</tr>
</tbody>
</table>

**Table 3. Results obtained from the protocol for cerebral vasospasm used to manage 52 patients suffering from aneurysmal subarachnoid hemorrhage.**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>% of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic vasospasm</td>
<td>13 (25.0)</td>
</tr>
<tr>
<td>Severe disability</td>
<td>3 (5.8)</td>
</tr>
<tr>
<td>Mild disability</td>
<td>2 (3.9)</td>
</tr>
<tr>
<td>Mortality rate from vasospasm</td>
<td>4 (7.7)</td>
</tr>
</tbody>
</table>

Figure 1. DSA (AP) views of a 20 year old woman presenting with symptomatic vasospasm, showing severe vasospasm. The arrow indicates the coiled anterior communicating artery aneurysm. Although all treatment options were used, she continued to decline until death.
ed well to antidepressant medication. Another developed grand mal seizures after his full recovery from severe vasospasm and he is maintained on anticonvulsant medications.

**Discussion**

Symptomatic cerebral vasospasm is the most significant cause of high mortality and morbidity in patients suffering aneurysmal SAH. It ranges in severity from mild and reversible to severe, leaving disabling deficits from ischemic changes in 7% of affected patients. Vasospasm can be severe enough to cause infarction and death in another 7% of patients. Angiographic vasospasm after ruptured aneurysm occurs in 30-70% of patients, while symptomatic vasospasm is seen in about one third of cases.11

The etiology of vasospasm is still under debate; the mechanism is related to the arterial blood clot and its spasmonogenic products.12 Oxyhemoglobin and free radicals produced by lysed red cells result in noxious effects on the endothelial cells and smooth muscle of the arterial wall. An influx of calcium ions and protein kinase C are implicated in the release of vasoconstricting substances, which leads to significant structural changes in the arterial wall including smooth muscle and myofibroblast proliferation, cellular necrosis, intimal hyperplasia and fibrosis, resulting in vasoconstriction. Removal of the blood clot and its products has been proposed to prevent these changes but the efficacy of this treatment has not been proven. However, calcium concentration in endothelial and smooth muscle cells may play a part in the pathogenesis of cerebral vasospasm.12-13 Increased nitric oxide in the endothelial cell membrane.19

One of the most recent vasoconstricting mediators is endothelin (ET-1) which is produced by the endothelial cells. It interacts with endothelin receptors located on smooth muscle cells and triggers vasoconstriction and proliferation of endothelial and smooth muscle cells.20,21 Recent studies have focused on discovering an effective antagonist to the endothelin receptors to block the cascade of the arterial wall reactions.22 Nevertheless, prolonged CV can be explained by the biomechanical and phenotypic reactions in response to SAH rather than from myogenic changes in the arterial wall.23

Numerous diagnostic tools and treatment options of vasospasm now exist. Most recent treatment modalities utilized can be grouped into direct or indirect pharmaceutical and mechanical vasodilators and neuroprotective agents.24,25 Further clinical trials are still needed to establish standard guidelines for the management of CV. Several diagnostic techniques have been used to predict CV. Computed tomography scanning (CT) is considered an important initial method for the prediction of vasospasm and its consequences. The large amount of blood on the initial CT scan is known to be a prognosticator of ischemia or even infarction from arterial vasospasm.1 Transcranial doppler sonography (TCD) can detect increased velocities in the basal segments of the anterior or posterior circulations. A rapid rise in velocity in the artery is usually associated with symptomatic vasospasm. Although it is feasible and non-invasive, TCD is less accurate than cerebral angiography in confirming vasospasm. It should be used to follow the progress of vasospasm.2,26

Although it is invasive, cerebral angiography is still the most accurate and standard tool for the diagnosis of vasospasm in addition to its value for endovascular treatment.27 New technologies such as CT perfusion scan, single photon emission computed tomography (SPECT) and magnetic resonance perfusion and diffusion scans may be employed to identify early ischemic foci in the brain before clinical vasospasm arises.19

Triple-H therapy consisting of hypervolemia, hemodilution and hypertension is a treatment designed to enhance cerebral blood flow (CBF) in ischemic zones and lower blood viscosity. It has been shown to offer benefits in many series, but it may not reduce overall morbidity and mortality. Increased blood volume can be obtained by using volume expanders or crystalloid fluids. Hemodilution can frequently occur passively with an optimum hematocrit goal of between 30% and 33% without affecting O2 carrying capacity. Elevating the systemic blood pressure can be introduced by volume expansion or pressors. Inducing hypertension may be risky with an unsecured aneurysm. It is necessary to monitor hemodynamics via appropriate indwelling catheters. The end point of triple-H therapy is significant brain edema or large infarction.28,29

The calcium entry blocking agent nimodipine has preferential cerebrovascular dilating effects, with potential use in the therapy and prevention of CV after aneurysmal SAH as it protects against delayed ischemic damage. Continuous infusion of nimodipine (20 mcg/kg/h) is initially given on admission and continued for 21 days. However, oral nimodipine (60 mg every four hours) can be continued for 21 days in the absence of clinical vasospasm. Nimodipine has been shown to decrease the incidence of CV and improve neurological outcome.24,25 Selective intraarterial nimodipine treatment is currently being suggested as a safe and effective treatment for CV.24,25 Intraoperative nimodipine infusion has also been trialled to prevent CV during intracranial aneurysm surgery with promising...
More recently, interest has emerged in the use of magnesium sulphate (MgSO4) as a neuroprotectant in obstetric patients with eclampsia and as a cerebral vasodilator for vasospasm. The role of MgSO4 in preventing vasospasm is questionable, but it may augment CBF by inducing vasodilation. Evidence obtained from experimental models of brain injury, stroke and SAH indicates that magnesium ions play a significant role as neuroprotective agents. Continuous infusion of high-dose magnesium has been suggested to prevent and treat delayed ischemic neurological deficit (DIND) in patients after ruptured aneurysm. The optimum therapeutic dose of MgSO4 is unknown, but continuous infusion of 64 mmol/L/day for 14 days after aneurysmal surgery has been shown to reduce the risk of vasospasm by 34% and improve outcome. Moreover, MgSO4 infusion which elevates the serum magnesium concentration to substantial therapeutic levels is well tolerated and safe, and has no major hemodynamic effects in patients with DIND.

When aggressive medical therapy fails to reverse ischemic deficits, prompt endovascular intervention is indicated. Vasospasm involving smaller arterial branches may be treated with an intraarterial infusion of vasodilators. Intraarterial papaverine is widely used; it produces clinical improvement in 43% of patients, augments CBF in another 60% of patients, and mean TCD velocities are improved. However, increased intracranial pressure, marked neurological deterioration and other complications are experienced with this mode of treatment, reaching 10% in some series. Overall supra selective intraarterial papaverine infusion is still highly recommended. Unfortunately, this dilatory effect tends to be short-lasting and requires repetition in cases of persistent vasospasm to improve CBF and outcomes. Nicardipine, another vasodilating agent, has also been trialled. Endovascular nicardipine therapy produced clinical improvement in 42% of patients, with significant improvement of mean TCD velocities, but only for four days. It was recommended as an endovascular treatment protocol for refractory vasospasm but this requires further evaluation.

Proximal vasospasm of larger vessels may be effectively treated with intraluminal balloon angioplasty. The benefit of this procedure is durable compared with intraarterial vasodilators. Clinical series assessing transluminal balloon angioplasty indicate clinical improvement in 62% of patients, with significant improvement of mean TCD velocities, but only for four days. It was recommended as an endovascular treatment protocol for refractory vasospasm but this requires further evaluation.

Barbiturate-induced coma can be of help in patients with vasospasm which is refractory to other therapies, to prevent life threatening neurological deficit. Barbiturates can ameliorate the harmful consequences of cerebral ischemia from vasospasm by reducing the neuronal metabolic rate and decreasing O2 consumption. Barbiturate therapy has shown an improvement in 45% of patients with no related deaths reported. Cardiovascular depression and sepsis are the major concerns for barbiturate use. Pentobarbital sodium is the most active cerebral vasodilator in this class of anesthetics. This agent inhibits the vasospastic activity of potassium, serotonin, and prostaglandins, and appears to be a calcium entry antagonist in the blood vessels. Cerebral perfusion pressure should be controlled by the use of vasopressors to offset the hypotensive effect of barbiturates. Barbiturate therapy is continued as long as vasospasm persists with high ICP. Therapeutic end point is ICP control. Following these guidelines, administration of barbiturates is believed to achieve good results.

More recently, promising results from the use of the endothelin A (ETA) receptor antagonist clazosentan may create new options for treatment of CV. Moreover, the probable role of E-selectin in the pathogenesis of vasospasm and the use of anti-E-selectin monoclonal antibody may help treatment. Further trials are required to confirm these results.
References


